Results 1 - 20 of 103 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial HypercholesterolemiaCirculation (New York, N.Y.), 2013-11, Vol.128 (19), p.2113-2120 [Peer Reviewed Journal]2013 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2014 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.113.004678 ;PMID: 24014831 ;CODEN: CIRCAZFull text available |
| 2 |
Material Type: Article
|
|
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsThe New England journal of medicine, 2015-04, Vol.372 (16), p.1500-1509 [Peer Reviewed Journal]Copyright © 2015 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1500858 ;PMID: 25773607Full text available |
| 3 |
Material Type: Article
|
|
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialThe Lancet (British edition), 2015-01, Vol.385 (9965), p.341-350 [Peer Reviewed Journal]Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 24, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61374-X ;PMID: 25282520 ;CODEN: LANCAOFull text available |
| 4 |
Material Type: Article
|
|
Cognitive Function in a Randomized Trial of EvolocumabThe New England journal of medicine, 2017-08, Vol.377 (7), p.633-643 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1701131 ;PMID: 28813214Full text available |
| 5 |
Material Type: Article
|
|
A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular RiskThe American journal of cardiology, 2016, Vol.117 (1), p.40-47 [Peer Reviewed Journal]The Authors ;2016 The Authors ;Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Jan 1, 2016 ;ISSN: 0002-9149 ;EISSN: 1879-1913 ;DOI: 10.1016/j.amjcard.2015.10.021 ;PMID: 26547291 ;CODEN: AJCDAGFull text available |
| 6 |
Material Type: Article
|
|
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 studyThe Lancet (British edition), 2012-12, Vol.380 (9858), p.1995-2006 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61771-1 ;PMID: 23141812 ;CODEN: LANCAOFull text available |
| 7 |
Material Type: Article
|
|
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin IntoleranceJournal of the American College of Cardiology, 2014-06, Vol.63 (23), p.2541-2548 [Peer Reviewed Journal]American College of Cardiology Foundation ;2014 American College of Cardiology Foundation ;Copyright Elsevier Limited Jun 17, 2014 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2014.03.019Full text available |
| 8 |
Material Type: Article
|
|
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialThe Lancet (British edition), 2015-01, Vol.385 (9965), p.331-340 [Peer Reviewed Journal]Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 24, 2015 ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0140-6736 ;ISSN: 1474-547X ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(14)61399-4 ;PMID: 25282519 ;CODEN: LANCAOFull text available |
| 9 |
Material Type: Article
|
|
A 52-Week Placebo-Controlled Trial of Evolocumab in HyperlipidemiaThe New England journal of medicine, 2014-05, Vol.370 (19), p.1809-1819 [Peer Reviewed Journal]Copyright © 2014 Massachusetts Medical Society. All rights reserved. ;2015 INIST-CNRS ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1316222 ;PMID: 24678979 ;CODEN: NEJMAGFull text available |
| 10 |
Material Type: Article
|
|
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialJournal of the American College of Cardiology, 2019-06, Vol.73 (23), p.2961-2970 [Peer Reviewed Journal]Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;2019. American College of Cardiology Foundation ;ISSN: 0735-1097 ;ISSN: 1558-3597 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2019.03.513 ;PMID: 31196453Full text available |
| 11 |
Material Type: Article
|
|
Effect of Evolocumab on Coronary Plaque CompositionJournal of the American College of Cardiology, 2018-10, Vol.72 (17), p.2012-2021 [Peer Reviewed Journal]2018 American College of Cardiology Foundation ;Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Oct 23, 2018 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2018.06.078 ;PMID: 30336824Full text available |
| 12 |
Material Type: Article
|
|
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]Journal of lipid research, 2016-06, Vol.57 (6), p.1086-1096 [Peer Reviewed Journal]2016 © 2016 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. ;Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc. 2016 ;ISSN: 0022-2275 ;EISSN: 1539-7262 ;DOI: 10.1194/jlr.P065334 ;PMID: 27102113Full text available |
| 13 |
Material Type: Article
|
|
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialThe American heart journal, 2016-03, Vol.173, p.94-101 [Peer Reviewed Journal]Mosby, Inc. ;2015 Elsevier Inc. ;Copyright © 2015 Elsevier Inc. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2016 ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2015.11.015 ;PMID: 26920601Full text available |
| 14 |
Material Type: Article
|
|
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 InhibitorClinical pharmacokinetics, 2018-07, Vol.57 (7), p.769-779 [Peer Reviewed Journal]The Author(s) 2018 ;Copyright Springer Nature B.V. Jul 2018 ;ISSN: 0312-5963 ;EISSN: 1179-1926 ;DOI: 10.1007/s40262-017-0620-7 ;PMID: 29353350Full text available |
| 15 |
Material Type: Article
|
|
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)Journal of the American College of Cardiology, 2014-04, Vol.63 (13), p.1278-1288 [Peer Reviewed Journal]American College of Cardiology Foundation ;2014 American College of Cardiology Foundation ;Copyright Elsevier Limited Apr 8, 2014 ;ISSN: 0735-1097 ;EISSN: 1558-3597 ;DOI: 10.1016/j.jacc.2014.01.006Full text available |
| 16 |
Material Type: Article
|
|
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 studyThe Lancet (British edition), 2012-12, Vol.380 (9858), p.2007-2017 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;2014 INIST-CNRS ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(12)61770-X ;PMID: 23141813 ;CODEN: LANCAOFull text available |
| 17 |
Material Type: Article
|
|
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismCirculation (New York, N.Y.), 2017-01, Vol.135 (4), p.338-351 [Peer Reviewed Journal]2017 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2016 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.116.025080 ;PMID: 27941065Full text available |
| 18 |
Material Type: Article
|
|
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialThe Lancet (British edition), 2011-08, Vol.378 (9792), p.676-683 [Peer Reviewed Journal]Elsevier Ltd ;2011 Elsevier Ltd ;2015 INIST-CNRS ;Copyright © 2011 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 20-Aug 26, 2011 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(11)61126-4 ;PMID: 21856481 ;CODEN: LANCAOFull text available |
| 19 |
Material Type: Article
|
|
Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension StudiesCirculation (New York, N.Y.), 2017-05, Vol.135 (19), p.1819-1831 [Peer Reviewed Journal]2017 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2017 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.116.025233 ;PMID: 28249876Full text available |
| 20 |
Material Type: Article
|
|
Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk: Primary Results From the Phase 2 YUKAWA StudyCirculation Journal, 2014, Vol.78(5), pp.1073-1082 [Peer Reviewed Journal]2014 THE JAPANESE CIRCULATION SOCIETY ;ISSN: 1346-9843 ;EISSN: 1347-4820 ;DOI: 10.1253/circj.CJ-14-0130 ;PMID: 24662398Full text available |
Results 1 - 20 of 103 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
Refine My Results
Creation Date
- Before 2004 (5)
- 2004 To 2009 (12)
- 2010 To 2013 (14)
- 2014 To 2018 (64)
- After 2018 (9)
-
More options
New Records
Resource Type
- Articles (102)
- Conference Proceedings (1)
-
More options
Subject
- Life Sciences & Biomedicine (74)
- Science & Technology (74)
- Humans (65)
- Cardiovascular System & Cardiology (52)
- Male (50)
- Cardiac & Cardiovascular Systems (49)
- Female (46)
- Aged (38)
- Middle Aged (38)
- Double-Blind Method (33)
- Cholesterol (32)
- Treatment Outcome (29)
- Cholesterol, Ldl - Blood (28)
- Adult (26)
- Proprotein Convertase 9 (23)
- Statins (22)
- Cardiovascular Disease (22)
- Hypercholesterolemia - Drug Therapy (22)
- Antibodies, Monoclonal - Therapeutic Use (21)
- Low Density Lipoprotein (20)
-
More options
Databases
- MEDLINE (66)
- Geneva Foundation Free Medical Journals at publisher websites (59)
- ProQuest Central (55)
- HighWire Press (Free Journals) (34)
- PubMed Central (17)
- DOAJ Directory of Open Access Journals (17)
- ProQuest One Psychology (14)
- Wiley Open Access Journals (11)
- ROAD: Directory of Open Access Scholarly Resources (5)
- Springer_OA刊 (2)
- Journals@Ovid Open Access Journal Collection Rolling (1)
- NORA - Norwegian Open Research Archives (1)
- ZORA (Open Access) (1)
- SAGE Open Access (1)
- ZORA (1)
- Lirias (KU Leuven Association) (1)
-
More options
Language
- Japanese (23)
- Russian (1)
- French (1)
-
More options
Journal Title
- Circulation (16)
- Clinical Cardiology (6)
- European Heart Journal (6)
- European Journal Of Heart Failure (4)
- Journal Of Lipid Research (3)
- Journal Of The American College Of Cardiology (20)
- New England Journal Of Medicine (3)
- The American Heart Journal (4)
- The Lancet (6)
- The New England Journal Of Medicine (7)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||